title: I.v. cocaine induces rapid, transient excitation of striatal neurons via its action on peripheral neural elements: single-cell, iontophoretic study in awake and anesthetized rats.
abstract: Cocaine's (COC) direct interaction with the dopamine (DA) transporter is usually considered the most important action underlying the psychomotor stimulant and reinforcing effects of this drug. However, some physiological, behavioral and psycho-emotional effects of COC are very rapid and brief and they remain intact during DA receptor blockade, suggesting possible involvement of peripheral non-DA neural mechanisms. To assess this issue, single-unit recording with microiontophoresis was used to examine changes in impulse activity of dorsal and ventral striatal neurons to i.v. COC (0.25-0.5 mg/kg) in the same rats under two conditions: awake with DA receptor blockade and anesthetized with urethane. In the awake preparation approximately 70% striatal neurons showed rapid and transient (latency approximately 6 s, duration approximately 15 s) COC-induced excitations. These effects were stronger in ventral than dorsal striatum. During anesthesia, these phasic effects were fully blocked and COC slowly decreased neuronal discharge rate. Cocaine-methiodide (COC-M), a derivative that cannot cross the blood-brain barrier, also caused phasic excitations in the awake, but not anesthetized condition. In contrast to regular COC, COC-M had no tonic effect on discharge rate in either preparation. Most striatal neurons that were phasically excited by both COC forms also showed short-latency excitations during tail-touch and tail-pinch in the awake preparation, an effect strongly attenuated during anesthesia. Finally, most striatal neurons that in awake conditions were phasically excited by somato-sensory stimuli and COC salts were also excited by iontophoretic glutamate (GLU). Although striatal neurons were sensitive to GLU in both preparations, the response magnitude at the same GLU current was higher in awake than anesthetized conditions. These data suggest that in awake animals i.v. COC, like somato-sensory stimuli, transiently excites striatal neurons via its action on peripheral neural elements and rapid neural transmission. While the nature of these neuronal elements needs to be clarified using other analytical techniques, they might involve voltage-gated K(+) and Na(+) channels, which have a high affinity for COC and are located on terminals of visceral sensory nerves that densely innervate peripheral vessels. Therefore, along with direct action on specific brain substrates, central excitatory effects of COC may occur via indirect action, involving afferents of visceral sensory nerves and rapid neural transmission. By providing a rapid sensory signal and triggering transient neural activation, such a peripherally triggered action might play a crucial role in the sensory effects of COC, thus contributing to learning and development of drug-taking behavior.
authors: Behavioral Neuroscience Branch, National Institute on Drug Abuse-Intramural Research Program, National Institutes of Health, DHHS, 5500 Nathan Shock Drive, Baltimore, MD 21224, USA. ekiyatki@intra.nida.gov
authors: E A
authors: EA
authors: Kiyatkin
authors: P L
authors: PL
authors: Brown
mesh_terms: D000200:Action Potentials / Q000187:drug effects; D000704:Analysis of Variance; D000758:Anesthesia; D000818:Animals; D003042:Cocaine / Q000008:administration & dosage*; D003342:Corpus Striatum / Q000166:cytology*; D018765:Dopamine Uptake Inhibitors / Q000008:administration & dosage*; D004333:Drug Administration Routes; D007275:Injections, Intravenous / Q000379:methods; D007478:Iontophoresis / Q000379:methods; D008297:Male; D009474:Neurons / Q000187:drug effects*; D051381:Rats; D020318:Rats, Long-Evans; D014851:Wakefulness / Q000502:physiology*
chemical_list: D018765:Dopamine Uptake Inhibitors; D003042:Cocaine
references: Brain Res. 1999 Mar 20;822(1-2):88-106
references: 10082887
references: J Neurosci. 1999 May 1;19(9):3594-609
references: 10212318
references: J Neurophysiol. 1999 May;81(5):2243-52
references: 10322063
references: Synapse. 2000 Mar 1;35(3):238-42
references: 10657032
references: Neuroscience. 2000;98(4):729-41
references: 10891616
references: Neuroscience. 2001;102(3):565-80
references: 11226694
references: Biochem Pharmacol. 1975 Apr 15;24(8):847-52
references: 1125084
references: Mol Pharmacol. 2001 May;59(5):1069-76
references: 11306689
references: J Pharmacol Exp Ther. 2001 Oct;299(1):220-6
references: 11561083
references: Pharmacol Biochem Behav. 1979 Dec;11(6):669-72
references: 119976
references: J Neurophysiol. 2002 Jul;88(1):300-5
references: 12091555
references: Behav Brain Res. 2002 Dec 2;137(1-2):27-46
references: 12445714
references: Pharmacology. 2003 May;68(1):49-56
references: 12660479
references: J Pharmacol Exp Ther. 1992 Nov;263(2):757-61
references: 1359115
references: J Pharmacol Exp Ther. 1992 Nov;263(2):734-41
references: 1432699
references: Eur J Neurosci. 2004 Nov;20(10):2838-42
references: 15548229
references: Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10023-8
references: 16006505
references: Eur J Neurosci. 2005 Aug;22(4):930-8
references: 16115216
references: J Membr Biol. 2005 Apr;204(3):129-36
references: 16245035
references: Neuroscience. 2006;138(1):257-80
references: 16377093
references: Mol Cells. 2005 Dec 31;20(3):315-24
references: 16404144
references: Basic Clin Pharmacol Toxicol. 2006 May;98(5):510-7
references: 16635111
references: BMC Neurosci. 2006 Jun 08;7:46
references: 16762059
references: Brain Res. 1991 Apr 19;546(2):287-96
references: 1676928
references: Neuropsychopharmacology. 2006 Nov;31(11):2341-8
references: 16855534
references: Eur J Neurosci. 2006 Aug;24(3):917-24
references: 16930419
references: Eur J Neurosci. 2006 Aug;24(4):1182-92
references: 16930444
references: Mol Neurobiol. 2006 Aug;34(1):1-26
references: 17003519
references: Neuropsychopharmacology. 2007 May;32(5):1141-58
references: 17019407
references: Neuropsychopharmacology. 2007 Jun;32(6):1232-41
references: 17151599
references: Eur J Pharmacol. 1991 Jun 6;198(2-3):203-5
references: 1864307
references: Brain Res. 1991 Apr 19;546(2):297-309
references: 2070264
references: J Pharmacol Exp Ther. 1990 Oct;255(1):154-60
references: 2213551
references: NIDA Res Monogr. 1989;95:146-51
references: 2561820
references: Int J Neurosci. 1989 Jan;44(1-2):111-33
references: 2562051
references: Psychiatry Res. 1989 Feb;27(2):117-25
references: 2652168
references: Addict Biol. 1998 Apr;3(2):189-96
references: 26734823
references: Science. 1987 Sep 4;237(4819):1219-23
references: 2820058
references: Psychopharmacology (Berl). 1986;90(1):142-3
references: 2876452
references: J Pharmacol Exp Ther. 1988 Aug;246(2):466-71
references: 2900325
references: Oral Surg Oral Med Oral Pathol. 1979 Oct;48(4):292-7
references: 291855
references: Pharmacol Biochem Behav. 1987 Feb;26(2):453-61
references: 3033700
references: Int J Neurosci. 1988 Sep;42(1-2):21-43
references: 3209370
references: Psychol Rev. 1987 Oct;94(4):469-92
references: 3317472
references: J Neurosci. 1988 Jan;8(1):100-12
references: 3339402
references: Prog Neuropsychopharmacol Biol Psychiatry. 1987;11(4):345-64
references: 3423267
references: Life Sci. 1987 Mar 16;40(11):1099-111
references: 3821374
references: Br J Anaesth. 1985 Oct;57(10):1006-11
references: 4041306
references: Arch Int Pharmacodyn Ther. 1971 Jan;189(1):198-208
references: 5130150
references: Psychopharmacology (Berl). 1982;78(3):204-9
references: 6296898
references: Brain Res. 1983 Oct;287(2):139-71
references: 6357356
references: Psychopharmacology (Berl). 1980 Feb;67(2):189-94
references: 6768094
references: Brain Res. 1983 Jan 10;258(2):217-28
references: 6824912
references: Pharmacol Biochem Behav. 1983 May;18(5):711-6
references: 6856646
references: Prog Neurobiol. 1980;14(2-3):69-97
references: 6999537
references: Brain Res. 1982 Jan 28;232(1):29-39
references: 7055709
references: J Neurosci. 1981 Aug;1(8):887-900
references: 7346593
references: Brain Topogr. 1995 Spring;7(3):209-16
references: 7599020
references: Brain Res Brain Res Rev. 1995 Jan;20(1):91-127
references: 7711769
references: Neuroscience. 1995 Feb;64(3):599-617
references: 7715774
references: J Neurosci. 1994 Dec;14(12):7735-46
references: 7996208
references: J Physiol. 1994 Jan 15;474(2):233-43
references: 8006810
references: Prog Brain Res. 1993;99:277-97
references: 8108553
references: J Neurosci. 1994 Mar;14(3 Pt 1):1224-44
references: 8120621
references: Neurosci Lett. 1993 Dec 24;164(1-2):175-8
references: 8152597
references: J Neurosci Methods. 1993 Apr;47(1-2):53-9
references: 8321014
references: Proc Natl Acad Sci U S A. 1993 Mar 15;90(6):2212-6
references: 8460124
references: J Neurosci. 1996 May 15;16(10):3459-73
references: 8627379
references: J Neurophysiol. 1996 Jan;75(1):142-53
references: 8822548
references: Physiol Behav. 1996 Jan;59(1):109-15
references: 8848468
references: Synapse. 1996 Nov;24(3):233-9
references: 8923663
references: Synapse. 1998 Feb;28(2):111-6
references: 9450511
references: J Neuropsychiatry Clin Neurosci. 1998 Spring;10(2):148-59
references: 9608403
references: Psychopharmacology (Berl). 1978 Apr 14;57(1):13-20
references: 96463
references: J Neurosci. 1998 Nov 1;18(21):9055-68
references: 9787009
references: Eur J Pharmacol. 1998 Dec 18;363(2-3):147-52
references: 9881582
references: J Cardiovasc Pharmacol. 1999 Jan;33(1):36-42
references: 9890394